tetano
Editor, Senior Moderator
Sci Adv
. 2025 Jan 31;11(5):eadq4545.
doi: 10.1126/sciadv.adq4545. Epub 2025 Jan 29. Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus
Richard A Adeleke[SUP] 1 [/SUP], Julie Sahler[SUP] 1 [/SUP], Annette Choi[SUP] 1 [/SUP], Kyle Roth[SUP] 1 [/SUP], Viraj Upadhye[SUP] 1 [/SUP], Shahrzad Ezzatpour[SUP] 1 [/SUP], Brian Imbiakha[SUP] 1 [/SUP], Solomiia Khomandiak[SUP] 1 [/SUP], Annika Diaz[SUP] 2 [/SUP], Gary R Whittaker[SUP] 1 [/SUP], Mason C Jager[SUP] 2 [/SUP], Avery August[SUP] 1 [/SUP], David W Buchholz[SUP] 1 [/SUP], Hector C Aguilar[SUP] 1 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses lead to severe respiratory illnesses and death in humans, exacerbated in individuals with underlying health conditions, remaining substantial global public health concerns. Here, we developed a bivalent replication-incompetent single-cycle pseudotyped vesicular stomatitis virus vaccine that incorporates both a prefusion-stabilized SARS-CoV-2 spike protein lacking a furin cleavage site and a full-length influenza A virus neuraminidase protein. Vaccination of K18-hACE2 or C57BL/6J mouse models generated durable levels of neutralizing antibodies, T cell responses, and protection from morbidity and mortality upon challenge with either virus. Furthermore, the vaccine provided heterologous protection upon challenge with a different influenza virus strain, supporting the advantage of using NA to increase the breadth of vaccine protection. Now, no bivalent vaccine is approved for use against both SARS-CoV-2 and influenza virus. Our study supports using this platform to develop safe and efficient vaccines against multiple viruses.
. 2025 Jan 31;11(5):eadq4545.
doi: 10.1126/sciadv.adq4545. Epub 2025 Jan 29. Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus
Richard A Adeleke[SUP] 1 [/SUP], Julie Sahler[SUP] 1 [/SUP], Annette Choi[SUP] 1 [/SUP], Kyle Roth[SUP] 1 [/SUP], Viraj Upadhye[SUP] 1 [/SUP], Shahrzad Ezzatpour[SUP] 1 [/SUP], Brian Imbiakha[SUP] 1 [/SUP], Solomiia Khomandiak[SUP] 1 [/SUP], Annika Diaz[SUP] 2 [/SUP], Gary R Whittaker[SUP] 1 [/SUP], Mason C Jager[SUP] 2 [/SUP], Avery August[SUP] 1 [/SUP], David W Buchholz[SUP] 1 [/SUP], Hector C Aguilar[SUP] 1 [/SUP]
Affiliations
- PMID: 39879304
- PMCID: PMC11777205
- DOI: 10.1126/sciadv.adq4545
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses lead to severe respiratory illnesses and death in humans, exacerbated in individuals with underlying health conditions, remaining substantial global public health concerns. Here, we developed a bivalent replication-incompetent single-cycle pseudotyped vesicular stomatitis virus vaccine that incorporates both a prefusion-stabilized SARS-CoV-2 spike protein lacking a furin cleavage site and a full-length influenza A virus neuraminidase protein. Vaccination of K18-hACE2 or C57BL/6J mouse models generated durable levels of neutralizing antibodies, T cell responses, and protection from morbidity and mortality upon challenge with either virus. Furthermore, the vaccine provided heterologous protection upon challenge with a different influenza virus strain, supporting the advantage of using NA to increase the breadth of vaccine protection. Now, no bivalent vaccine is approved for use against both SARS-CoV-2 and influenza virus. Our study supports using this platform to develop safe and efficient vaccines against multiple viruses.